Background: Weight management is considered a key therapeutic strategy in type 2 diabetes mellitus. However, little is known about the impact of weight loss or body mass index (BMI) reduction on type 2 diabetes-related healthcare costs. Objective: The aim of this study was to estimate the economic impact of change in BMI among patients with type 2 diabetes mellitus from the Spanish healthcare system perspective. Methods: The ECOBIM study is an observational, non-interventional study in which data on BMI change and costs incurred by patients with type 2 diabetes were collected cross-sectionally and retrospectively for a 12-month period. Generalized linear mixed models were applied to estimate the effects of (i) BMI change in general (one-slope model); (ii) BMI gain and no BMI gain (two-slope model); and (iii) BMI gain and no BMI gain among obese and non-obese patients (four-slope model). Results: We studied 738 patients with a mean (SD) age of 66 (11) years and BMI of 30.6 (5.2) kg/m
Introduction
Type 2 diabetes mellitus is one of the leading causes of morbidity and mortality in Europe. [1] Currently, about 285 million people worldwide have diabetes and this number is expected to reach 439 million by 2030. [2] The prevalence of diabetes mellitus in Spain is currently estimated at 8.7%, and type 2 diabetes accounts for about 90% of cases. [3, 4] Type 2 diabetes and its complications confer a substantial economic burden on health systems and society that is expected to increase as the prevalence of diabetes increases. [1, 5, 6] In Spain, during 2002, the total direct medical costs of type 2 diabetes have been estimated at between h2.4 and h2.7 billion, which corresponds to approximately 6.3-7.4% of total public health expenditure. [7] Estimates of the mean type 2 diabetes annual direct costs in Spain are in the range of h1290-h3009 per patient. [7] [8] [9] [10] Patients with type 2 diabetes are at increased risk of cardiovascular disease owing to concomitant presence of cardiovascular risk factors such as obesity, hypertension, dyslipidaemia and tobacco use. [11] Obesity is the most significant risk factor in the development of major complications associated with type 2 diabetes. [12, 13] According to a recent estimate, 84% of patients with type 2 diabetes in Spain were either pre-obese, defined by a body mass index (BMI) of >25 kg/m 2 and <30 kg/m 2 , or obese (BMI ‡30 kg/m 2 ), [14] although these estimations would be higher if body composition techniques were considered a diagnostic tool. [15] The prevalence of type 2 diabetes increases with the severity of obesity. [16, 17] Together, type 2 diabetes and obesity lead to a higher incidence of diabetes-related complications and cardiovascular events, [18, 19] which translates into increased economic costs for national health systems. [1] Likewise, a very recent study in diabetes patients with BMI ‡35 kg/m 2 reported that clinical benefits of bariatric surgery translated into considerable economic benefits. [20] Furthermore, diabetes-related complications and/ or obesity adversely affect patients' healthrelated quality of life (HR-QOL), [21] [22] [23] [24] primarily in the physical domain. Although studies have assessed the clinical benefit of weight loss in patients with type 2 diabetes, [25] [26] [27] little is known about the impact of weight loss or BMI reduction on type 2 diabetes care costs. The objective of the present study was to estimate the effect of BMI change in short-term economic costs of type 2 diabetes care from the Spanish healthcare system perspective.
Materials and Methods

Study Design
The ECOBIM (Economic Impact of BMI on Cost Associated with the Management of Patients with type 2 Diabetes Mellitus) study was an observational, non-interventional, multicentre study conducted in Spain. It consisted of a 12-month observation period (study reference period) for which data were collected retrospectively and cross-sectionally from patients' medical charts at the study visit (figure 1). All data were provided during usual care and no additional visits, tests or interventions were required. The protocol was approved by Hospital Universitario La Paz ethics committee (Madrid, Spain) and conducted in accordance with the Spanish regulation for observational studies and the Declaration of Helsinki. Patients volunteered for the study and authorized the use of their data according to defined provisions in Law 15/1999 of 13 December on the Protection of Personal Data.
Study Population and Investigators
Patients included men and women aged over 30 years who had been diagnosed with type 2 diabetes by the investigator based on the American Diabetes Association (ADA) criteria [4] at least 24 months prior to their inclusion. Eligible patients had been followed during the normal course of outpatient care, either in the hospital or in the investigator's private practice, and had relevant information available in their medical records for at least 24 months prior to study inclusion (information regarding weight was collected [and used] from medical records 12, 18 and 24 months prior to the beginning of the study). Patients were excluded if they had been diagnosed with type 1 diabetes mellitus or diabetes secondary to other diseases, were female patients pregnant during the observation period, or had participated in any other clinical study 24 months prior to the inclusion in the ECOBIM study. Each site could recruit up to six patients on consecutive days. For each day, the first patient meeting the screening criteria and with a scheduled visit during the study inclusion period was included. Participating centres were selected so that the geographic distribution and investigator type (general practitioners and specialists) were representative of the physician population treating patients with type 2 diabetes in Spain.
Data Collection and Cost Assessment
At the study visit, sociodemographic, clinical and healthcare resource utilization data related to diabetes and its complications were collected from the medical records for the 12-month study reference period. Clinical data collected included anthropometric characteristics, time since type 2 diabetes diagnosis, diabetes-related complications, cardiovascular risk factors, glycaemic control (glycosylated haemoglobin A 1c [HbA 1c ], and fasting plasma glucose [FPG] ). Healthcare resource data included visits to healthcare professionals (primary care and specialist physicians, and other professionals such as dieticians or podiatrists), emergency room visits, hospitalizations, diabetes treatment, other related co-morbidities, and use of blood glucose monitoring strips.
The key variables were the change in BMI and direct healthcare costs over the 12-month study reference period. BMI was calculated from weight and height measurements at the study visit and from weight measurements at 12 -1 months prior to the study visit (the beginning of the study reference period). Healthcare costs were collected over the same 12-month period. In order to avoid under-reporting of healthcare resource usage (based on medical record data), patients were asked several questions during the study visit regarding their use of healthcare resources during the previous (observational period) year. These questions served as a quality check of the medical record entries and elicited any missing data. Costs related to direct healthcare resources were obtained from the OBLIKUE database of Spanish Impact of BMI Change on T2DM-related Costs in Spainhealthcare costs for the year 2008. [28] Unit cost of medications for the treatment of type 2 diabetes and related co-morbidities were obtained from the BOT database (General Council of Official Colleges of Pharmacists of Spain). [29] In addition, patients completed two HR-QOL questionnaires at the study visit: the EuroQol-5D (EQ-5D) health questionnaire [30] and a Spanish version of the Diabetes Quality of Life (DQOL) questionnaire. [31] Statistical Analysis
The study was planned to include 779 patients, allowing the detection of a low correlation between BMI and direct diabetes costs (0.1) at a significance level of 0.05 and with a statistical power of 0.80. Based on the change in BMI during the study reference period, the patients were classified as BMI gainers (change in BMI >0) and non-BMI gainers (patients who experienced either a loss or no change in BMI). The demographic and clinical characteristics for these two subgroups were assessed using descriptive summary statistics. Means and standard deviations (SDs) were calculated for continuous variables. Absolute frequencies and percentages were calculated for categorical variables. All percentage calculations were based on the number of patients studied. Univariate comparisons were performed between BMI gainers and non-BMI gainers: Chi-square tests or the Cochran-Armitage trend test were used to compare categorical variables. Wilcoxon tests and analyses of covariance were used to compare continuous variables. Mean, SD and median for direct 1-year healthcare costs in the BMI-gainer and non-BMI-gainer subgroups were also calculated and compared descriptively using Wilcoxon tests. In addition, 95% confidence intervals for mean cost were derived via bootstrapping.
Generalized linear mixed models (GLMMs) provide a flexible way to model production traits that do not satisfy the assumptions of an ordinary least-square regression, e.g. cost data. [32] Therefore, the economic impact of BMI change on type 2 diabetes total direct costs was assessed using three GLMMs with a log link function and gamma error distribution. The estimated regression coefficient was transformed to euros and expressed as percentage change in the total direct cost for each unit (1 kg/m 2 ) increase or decrease in BMI.
In GLMM model 1 (one-slope model), the direct cost of diabetes (absolute values) was analysed according to the BMI at 12 months prior to the study visit, including the cost as dependent variable and the BMI as independent variable. This allowed the estimation of the impact that an increase of one BMI unit had on the direct cost per patient. In GLMM model 2 (twoslope model), the direct cost of diabetes was analysed according to the change in BMI from baseline to 12 months during the study reference period (i.e. gain vs no gain), and the interaction between both variables. Statistically significant differences in cost between BMI gainers and non-BMI gainers could be detected owing to the addition of the interaction term in the model. This analysis resulted in separate slope estimates for BMI gainers and non-BMI gainers.
Based on GLMM model 2, GLMM model 3 (four-slope model) allowed the study of statistically significant differences in direct diabetes costs among BMI gainers and non-BMI gainers according to obesity status, i.e. in patients defined according to the World Health Organization [13] as obese (BMI ‡30 kg/m 2 ) or non-obese (BMI <30 kg/m 2 ) at the study visit. Change in BMI during the study reference period, obesity status at the study visit and the corresponding interaction terms were included as independent regression variables. This analysis resulted in separate slope estimates at baseline for (i) BMI gainer, obese patients; (ii) BMI gainer, non-obese patients; (iii) non-BMI gainer, obese patients; and (iv) non-BMI gainer, non-obese patients.
Variables that could potentially confound the observed associations were included in all these models as independent regression variables. These included baseline sociodemographic and clinical variables, diabetes treatment information, DQOL, EQ-5D, work productivity, and diabetes-related microvascular and macrovascular complications. For all three GLMM models, the selection process was as follows. First, individual GLMMs were performed (with direct cost as dependent variable and each variable as independent regression variable) in order to detect factors related to the total direct cost. In a second step, the variables that were found to be significant in the individual models were then used to build the multivariate model. Results regarding the first step of the multivariate model build are provided in table S1 of the Supplemental Digital Content, http://links.adisonline. com/APZ/A62. Missing values were not imputed. These three multivariate GLMMs were also replicated using weight instead of BMI.
Statistical significance was evaluated at the 0.05 level. Statistical Analysis System Ò software version 8 (SAS Institute, Inc., Cary, NC, USA) was used for all analyses.
Results
The study was conducted in Spain by 80 investigators (25 primary care physicians, 27 endocrinologists and 28 specialists in internal medicine) at 80 sites located either in hospitals or private practices (these data refer only to sites and investigators who contributed the 757 patients entered in the study). A total of 757 patients entered the study between March and November 2008, 738 of whom were eligible for analysis. Of the eligible patients, 304 (41.2%) were categorized as BMI gainers and 434 (58.8%) as non-BMI gainers. Among the non-BMI gainers, 385 (52.2% of the total eligible population) showed BMI loss and 49 (6.6%) showed no BMI change.
Patient Characteristics
Overall, the mean age was 66 years and 54.2% of the 738 patients were males (table I). Most patients were Caucasian (97.0%), 71.8% were educated to primary level at most, 42.7% were retired, and 59.8% had never smoked. The number of patients unable to work because of diabetes was relatively low (1.9%), so was the number of patients unable to work due to other reasons (BMI gainers: 4.9% and non-BMI gainers: 2.1%). The mean time since diabetes diagnosis was statistically significantly higher in BMI gainers (12 years) than non-BMI gainers (10 years) [p < 0.01]. Most patients had been on non-insulin treatment only during the last 12 months (BMI gainers 53.3%; non-BMI gainers 67.7%). A quarter (25.5%) had used both insulin and non-insulin treatment (BMI gainers 32.9% and non-BMI gainers 20.3%) and 8.9% (BMI gainers 10.9%, non-BMI gainers 7.6%) had used only insulin. Overall, 46 patients (6.2%) initiated insulin during the 12-month observational period. Regarding the use of metformin, 160 (52.6%) of the BMI gainers and 294 (67.4%) of non-BMI gainers had used metformin alone or in combination with insulin or other oral antidiabetic drugs (sulphonylureas and thiazolidinediones).
BMI gainers and non-BMI gainers had a similar mean waist circumference 12 months prior to baseline, but BMI gainers had a statistically significantly greater waist circumference than non-BMI gainers at the study visit (p < 0.001) [table II]. BMI gainers also had significantly higher mean HbA 1c and FPG values than non-BMI gainers at the study visit (both p < 0.001). With the exception of triglycerides (p = 0.008), no statistically significant differences were observed for lipids and blood pressure at the study visit (table II) .
Direct Healthcare Costs
During the study reference period, the average 1-year total direct healthcare cost for the entire study population was h2336.67 per patient (median h1683.27). This cost comprised a pharmacy cost of h1512.48 (median h1192.40) and a medical cost of h828.29 (median h242.56) [table III]. The mean pharmacy cost was higher than the medical cost in both the BMI gainers and the non-BMI gainers. The bulk of the pharmacy costs in both groups (approximately 75%) was due to costs of blood glucose monitoring and diabetesrelated medication. If we compare between groups, the mean pharmacy cost was significantly higher (p = 0.0054) in the BMI gainers than in the non-BMI gainers. This finding was attributable to significantly higher costs for insulin (p < 0.001) and for blood glucose monitoring (p < 0.001) among BMI gainers. The mean medical cost was lower in the BMI gainers (h784 vs h859), but the difference was not statistically significant. Three GLMMs were used to explore the association of diabetes-related healthcare costs with BMI change during the 12-month study reference period. Due to missing values, only data of 517 patients could be used (BMI gainers: 198 patients; non-BMI gainers: 319 patients). These patients had a mean age of 65 years and 57.6% were male. The mean time since diagnosis of diabetes was 11 years for BMI gainers and 9 years for non-BMI gainers (p = 0.079). The majority of patients had never smoked (59.0%). Most patients had been on non-insulin treatment only during the last 12 months (BMI gainers 57.6%; non-BMI gainers 72.4%). Overall, 22.8% had used both insulin and non-insulin treatment (BMI gainers 31.3% and non-BMI gainers 17.6%) and 6.2% (BMI gainers 7.6%; non-BMI gainers 5.3%) had used only insulin. Regarding the use of metformin, 112 (56.6%) of the BMI gainers and 177 (55.5%) of non-BMI gainers had used metformin alone or in combination.
In model 1 (one-slope model), a unit gain in BMI was statistically significantly (p < 0.001) associated with an increase of 2.4% in total direct costs ( figure 2 and table IV) . When the effects of BMI gain and no BMI gain during the study reference period were assessed separately for BMI gainers and non-BMI gainers (model 2, twoslope model), a one-unit change in BMI was associated in BMI gainers with a 20.0% increase in costs, but in non-BMI gainers with an 8.0% decrease in costs (p < 0.01 for the comparison of subgroups, table IV).
Model 3 (four-slope model) examined the association of BMI change with 1-year direct costs during the study reference period according to patients' obesity status at the study visit. Among non-BMI gainers, a one-unit decrease in BMI was associated with a decrease of 9.4% in total direct costs in obese patients and a decrease of 2.7% in non-obese patients (table IV) . Among BMI gainers, a one-unit increase in BMI was associated with an increase of 19.6% and 18.7% in total direct costs in obese and non-obese patients, respectively.
Similar patterns of results were obtained when weight, instead of BMI, was applied in the three GLMM models. In model 1, a gain of 1 kg was significantly (p = 0.003) associated with an increase BG = blood glucose; BMI = body mass index; n = number of patients; N = total population size; TZD = thiazolidinediones.
of 0.8% in total direct costs. When weight changes during the study reference period were modelled separately for weight gainers (patients who experienced gain in weight) and non-weight gainers (patients who experienced either loss or no change in weight), every unit gain in weight was associated with a 7.6% increase in total direct costs, while a loss of 1 kg was associated with a 2.8% decrease in total direct costs (model 2). According to model 3, for the non-weight gainers, the economic benefit association with a reduction in weight was greater in obese patients (3.4% decrease in total direct costs per 1 kg of weight lost) than in non-obese patients (0.7% decrease per 1 kg of weight lost). Among weight gainers, a 1 kg increase in weight was associated with an increase of 7.8% and 6.4% in total direct costs in obese and non-obese patients, respectively.
Discussion
Obesity is a significant determinant of healthcare costs, since it predisposes patients to chronic and costly medical conditions such as type 2 diabetes. [33] The observational ECOBIM study was designed to assess the relationship between 1-year direct healthcare costs and BMI change in patients with type 2 diabetes in Spain. Its results have important implications for clinicians involved in the management of patients with type 2 diabetes and the associated complications and co-morbidities.
Mean pharmacy costs over 1 year were almost twice the medical costs in both the BMI-gainers and the non-BMI-gainers groups within the ECOBIM population, owing mainly to costs of blood glucose testing and diabetes-related medication. This is in line with a previous study on the economic costs associated with type 2 diabetes in Spain. [8] The authors reported that medications were the major cost driver (42% of annual direct healthcare costs per patient), with non-diabetesrelated drugs accounting for the main proportion in the overall pharmacological costs (76%). Focusing on the difference between both groups in the pharmacy costs, the higher percentage of a BMI gainers: patients whose BMI increased during the 12 months prior to the study visit. Non-BMI gainers: patients who experienced no gain in BMI, i.e. either a loss (n = 385) or no change (n = 49) during the 12 months prior to the study visit.
b For all variables except weight and BMI, comparisons were performed by analyses of covariance with the value at study visit as the dependant variable, the BMI cohort as independent factor and the value at 12 months prior to the study visit as covariable. patients with insulin treatment among BMI gainers (44% vs 28%) could explain the approximately 1.5-fold higher costs for insulin treatment and blood glucose monitoring in this cohort. In contrast to the pharmacy costs, the mean medical cost in ECOBIM was approximately 9% lower in BMI gainers than in non-BMI gainers. This difference was not statistically significant and its importance is unclear. Mean hospitalization costs were statistically significantly higher in non-BMI gainers. As the variability of hospitalization costs was also large in this group compared with the BMI gainers, mean costs for non-BMI gainers may have been influenced by some patients with very long stays at the hospital and therefore very high individual costs. Although there is some evidence for a reduction of healthcare costs in patients at very high BMI levels (>36 kg/m 2 ), increasing body mass is directly associated with an increasing use of healthcare services over the range of BMI observed in the ECOBIM study. [34] Overall, among ECOBIM participants, a oneunit gain in BMI was statistically significantly associated with a 2.4% increase in total direct costs (p < 0.001), a one-unit change in BMI gainers was associated with a 20.0% increase in total costs, while in non-BMI gainers, a one-unit decrease in BMI was associated with an 8.0% decrease in total costs (p < 0.01 for the comparison between BMI/non-BMI gainers). The estimated a Non-BMI gainers: patients who experienced no gain in BMI, i.e. either a loss (n = 385) or no change (n = 49) during the 12 months prior to the study visit.
b All values are mean (SD). In addition, 95% confidence intervals for the mean costs generated using bootstrapping methods are provided. Wilcoxon tests were used for statistical comparisons of continuous variables.
c For non-BMI gainers, missing values account for the difference between the total healthcare cost and the sum of medical and pharmacy costs.
d Diabetes-related medication: other than insulin and OADs. BMI = body mass index; OAD = oral antidiabetic medication.
economic benefit of BMI reduction was approximately 3-fold greater in obese patients than in non-obese patients. These results are consistent with previous findings. Over a decade ago, it was estimated that an increase of one BMI unit among the general population in the US was associated with a 7% increase in total healthcare expenditure in males and a 16% increase in females. This increase in costs was attributed to the increased risk of chronic illnesses such as type 2 diabetes, although no significant relationship was observed when patients with specific illnesses were analysed. [34] Another study that combined information from patient surveys, medical chart reviews and health insurance claims estimated that, among individuals with type 2 diabetes, every unit increase in BMI (over 30 kg/m 2 ) increased annual direct medical costs by 1%. [35] More recently, Yu et al. [33] analysed healthcare database information in the US and found that the mean total healthcare cost over 12 months was approximately 30% higher among patients with type 2 diabetes who gained weight over a 6-month observation period than among those who did not gain weight (p = 0.046). Diabetesrelated costs were 14% higher among weight gainers than non-weight gainers (p = 0.006). According to a GLMM analysis, a 1% change in weight was associated with an approximately 3% change in total diabetes-related costs (p < 0.01). When modelled separately, weight loss was significantly associated with a reduction in costs, while weight gain was not statistically significantly associated with an increase. As in the present study, the benefit of weight loss was most pronounced in obese patients, in whom a 1% reduction in weight was associated with a 6.7% decrease in diabetes-related costs (p < 0.01). [34] Further evidence supports the conclusion that weight loss is associated with a reduction of economic costs among obese patients with type 2 diabetes. A small, prospective study assessed the effect of an intensive, 12-week weight reduction programme on prescription costs in obese patients with type 2 diabetes (n = 40). [36] The mean observed weight loss of 14.8% at the end of the programme was associated with a 49% reduction in prescription costs at 1 year. Data from a modelling study in the general population also suggest that a weight loss of 10% may yield substantial long-term economic benefits, mostly owing to reductions in the costs of type 2 diabetes, coronary heart disease and hypertension. [37] Lifetime economic costs were reduced by up to $US5300 (year 1996 values) with the greatest benefits in patients at the highest initial BMI levels. Results obtained from a recent study that analysed the clinical and economic benefits of bariatric surgery in obese (BMI ‡35 kg/m 2 ) diabetic patients support the conclusion made in this study. [21] The present study has certain limitations. First, the economic benefit associated with weight loss was measured over a short-term period of 12 months. Further data are required on the effect of weight and/or BMI change on long-term direct costs in patients with type 2 diabetes, together with the factors that underlie variations in weight. Second, the measurement of BMI change in parallel with 1-year direct costs may confound the interpretation of the relationship between these variables because events such as hospitalization and emergency room visits could contribute to a change in BMI or weight, as well as to the related medical cost. Third, because of bureaucratic difficulties, centres across all Spanish regions but two (Paı´s Vasco and Navarra) participated in the study; these two regions represent around 6.1% [38] of the national population. 
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Fourth, due to the observational nature of the study, the data registry started after patients had signed the informed consent, therefore patient response rate has not been collected. Fifth, because of the way data have been collected, it was not possible to separate cost into that attributable to diabetes, diabetic complications and comorbidities. Sixth, due to missing values, only data of 517 patients could be used; despite the fact that no obvious differences were observed between these 517 patients and the overall 738, this could nevertheless have weakened the generalization of the findings. Seventh, the study cannot explain the possible reasons for BMI or weight change during the reference period. Many factors could have contributed to the observed changes, including diabetes-and non-diabetesrelated medications, diet, physical exercise, disease severity, and other related co-morbidities. In the future, the economic consequences of BMI or weight change should ideally be studied in various subgroups categorized by gender, age, duration of diabetes, diabetes-related complications, diabetes treatment and selected co-morbidities. Lastly, data on healthcare resource utilization were collected retrospectively and therefore may not be complete. An attempt was made to overcome this problem by asking patients to complete this information, where necessary, at the study visit.
Conclusions
An increase in BMI among patients with type 2 diabetes in Spain was associated with increased 1-year direct healthcare costs. A reduction in BMI was associated with appreciable short-term economic benefits, especially in obese patients. 
